Clinical Trial Update: Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain [Phase 3]

View source ↗

Summary

Phase 3 trial update of alvimopan (Entereg) for opioid-induced constipation in patients with persistent non-cancer pain; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation
• Opioid-induced Constipation

Drugs mentioned

• Entereg (alvimopan)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Bowel Dysfunction, Constipation | Phase 3 | Status: COMPLETED